Medicare Part D Inflation Rebates: January 9 Deadline Approaching

As the January 9 deadline for Medicare Part D Inflation Rebates approaches, drug manufacturers are entering one of the most consequential compliance checkpoints introduced under the Inflation Reduction Act (IRA). These rebate requirements extend beyond routine reporting and demand careful coordination across pricing, contracting, and compliance teams to avoid downstream financial and regulatory risk. In this blog, we highlight why this deadline matters and how manufacturers can take practical steps now to mitigate risk and maintain confidence in their Part D rebate submissions.

What’s Due—and When

The Medicare Part D Inflation Rebate program requires manufacturers to pay rebates when drug price increases exceed inflation. While primarily focused on branded drugs, there are situations in which generic drugs are subject to these penalties. It’s also important to note that the penalty is calculated differently than the Medicaid inflation penalty and uses a different baseline period. CMS is currently billing for the following periods:

• October 1, 2022 – September 30, 2023
• October 1, 2023 – September 30, 2024

Manufacturers must ensure rebate amounts for both periods are accurate and paid in full by January 9, 2026.

The Risk of Non-Compliance

Failure to pay the full rebate amount by the deadline may result in a civil monetary penalty equal to 125% of the rebate owed. Given the size of this potential exposure, accuracy and timeliness are essential.

Why Reconciliation Matters

A common challenge is misalignment between:

• Manufacturer-calculated and reported rebate amounts, and
• CMS-billed rebate amounts

Reconciling these figures prior to payment is critical to ensure the correct amount is paid, support audit readiness, and reduce the risk of penalties or rework.

How Prescription Analytics Is Supporting Clients

For Prescription Analytics clients, this reconciliation effort is already well underway. Our Government Pricing experts are actively working alongside pharmaceutical manufacturers to bring clarity and structure to the Part D inflation rebate process.

Current support includes:

• Reconciling CMS-billed rebates against reported calculations
• Resolving discrepancies ahead of payment
• Coordinating with clients to support accurate, timely submissions

Our goal is to minimize uncertainty and help manufacturers meet their obligations with confidence.

Take Action Now

With the January 9 deadline quickly approaching, proactive reconciliation and coordination are key. Waiting until after payment increases risk and complexity.

For additional background on the Inflation Reduction Act and its impact on manufacturers, visit our website and read our IRA blog.

Accuracy. Timeliness. Compliance. That’s how Medicare Part D Inflation Rebates should be managed.